Tags

Type your tag names separated by a space and hit enter

Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers.
Ann Clin Biochem. 2006 Mar; 43(Pt 2):135-45.AC

Abstract

AIMS

To review 'Diabetes Control and Complications Trial (DCCT)-aligned' HbA(1c) reporting in UK, use of individual/network equations relating IFCC calibration to 'DCCT alignment', and whether HbA(1c) in the presence of variant haemoglobins is, according to manufacturers, suitable for current, clinical guidelines.

METHODS

Questionnaire sent to nine manufacturers and responses analysed.

RESULTS

All methods were certified as 'DCCT-aligned' by National Glycohemoglobin Standardization Program (NGSP); UK EQA schemes reported 95% of results 'DCCT-aligned' in December 2004. The master equation relating networks was used by six manufacturers and specific equations for individual methods by three. HbA(1c) results from laboratory/point of care testing analysers can be affected by variant haemoglobins including elevated HbF; only IE HPLC (and LPLC) detect their presence. If chromatographic separation is ideal in heterozygous patients, laboratories either choose not to report HbA(1c) and propose another strategy for monitoring glycaemia, or report HbA(1c) and issue a caution that it may not be appropriate for guidelines. HbA(1c) reported from immunochemistry or affinity chromatography in presence of variant haemoglobins, may not be reliable for use with clinical guidelines.

CONCLUSIONS

For clinical care, HbA(1c) must reflect its relationship to glycaemia in clinical trials underpinning national guidelines. A flowchart to establish if HbA(1c) measurement is appropriate has been produced for use in a clinical setting.

Authors+Show Affiliations

Department of Clinical Biochemistry, University Hospital Birmingham NHS Trust, Selly Oak Hospital, Raddlebarn Road, Birmingham, B29 6JD, UK. susan.manley@uhb.nhs.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

16536916

Citation

Manley, S E., et al. "Calibration of HbA1c and Its Measurement in the Presence of Variant Haemoglobins: Report On Questionnaire to Manufacturers." Annals of Clinical Biochemistry, vol. 43, no. Pt 2, 2006, pp. 135-45.
Manley SE, Round RA, Smith JM. Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers. Ann Clin Biochem. 2006;43(Pt 2):135-45.
Manley, S. E., Round, R. A., & Smith, J. M. (2006). Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers. Annals of Clinical Biochemistry, 43(Pt 2), 135-45.
Manley SE, Round RA, Smith JM. Calibration of HbA1c and Its Measurement in the Presence of Variant Haemoglobins: Report On Questionnaire to Manufacturers. Ann Clin Biochem. 2006;43(Pt 2):135-45. PubMed PMID: 16536916.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers. AU - Manley,S E, AU - Round,R A, AU - Smith,J M, PY - 2006/3/16/pubmed PY - 2006/4/28/medline PY - 2006/3/16/entrez SP - 135 EP - 45 JF - Annals of clinical biochemistry JO - Ann Clin Biochem VL - 43 IS - Pt 2 N2 - AIMS: To review 'Diabetes Control and Complications Trial (DCCT)-aligned' HbA(1c) reporting in UK, use of individual/network equations relating IFCC calibration to 'DCCT alignment', and whether HbA(1c) in the presence of variant haemoglobins is, according to manufacturers, suitable for current, clinical guidelines. METHODS: Questionnaire sent to nine manufacturers and responses analysed. RESULTS: All methods were certified as 'DCCT-aligned' by National Glycohemoglobin Standardization Program (NGSP); UK EQA schemes reported 95% of results 'DCCT-aligned' in December 2004. The master equation relating networks was used by six manufacturers and specific equations for individual methods by three. HbA(1c) results from laboratory/point of care testing analysers can be affected by variant haemoglobins including elevated HbF; only IE HPLC (and LPLC) detect their presence. If chromatographic separation is ideal in heterozygous patients, laboratories either choose not to report HbA(1c) and propose another strategy for monitoring glycaemia, or report HbA(1c) and issue a caution that it may not be appropriate for guidelines. HbA(1c) reported from immunochemistry or affinity chromatography in presence of variant haemoglobins, may not be reliable for use with clinical guidelines. CONCLUSIONS: For clinical care, HbA(1c) must reflect its relationship to glycaemia in clinical trials underpinning national guidelines. A flowchart to establish if HbA(1c) measurement is appropriate has been produced for use in a clinical setting. SN - 0004-5632 UR - https://www.unboundmedicine.com/medline/citation/16536916/Calibration_of_HbA1c_and_its_measurement_in_the_presence_of_variant_haemoglobins:_report_on_questionnaire_to_manufacturers_ L2 - https://journals.sagepub.com/doi/10.1258/000456306776021508?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -